QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Forecast, Price & News

$0.36
+0.00 (+0.45%)
(As of 05:12 PM ET)
Compare
Today's Range
$0.36
$0.40
50-Day Range
$0.36
$0.93
52-Week Range
$0.30
$8.35
Volume
228,391 shs
Average Volume
507,249 shs
Market Capitalization
$15.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Eiger BioPharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,469.7% Upside
$5.67 Price Target
Short Interest
Healthy
2.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($0.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

239th out of 968 stocks

Biological Products, Except Diagnostic Industry

30th out of 160 stocks


EIGR stock logo

About Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR Price History

EIGR Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Eiger to discontinue hepatitis drug study
Citi Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EIGR Company Calendar

Last Earnings
8/14/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,481.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-96,780,000.00
Net Margins
-618.36%
Pretax Margin
-618.35%

Debt

Sales & Book Value

Annual Sales
$13.48 million
Book Value
$1.25 per share

Miscellaneous

Free Float
42,728,000
Market Cap
$15.88 million
Optionable
Not Optionable
Beta
1.64
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. David Apelian M.B.A. (Age 58)
    M.D., MBA, Ph.D., CEO & Director
    Comp: $204.39k
  • Dr. Jeffrey S. Glenn M.D. (Age 60)
    Ph.D., Scientific Founder & Independent Director
    Comp: $67k
  • Mr. Eldon C. Mayer IIIMr. Eldon C. Mayer III (Age 62)
    M.B.A., Chief Commercial Officer
    Comp: $586.96k
  • Mr. William G. Kaichoff CPA (Age 57)
    CPA, CFO and Principal Financial & Accounting Officer
  • Mr. Christopher A. Kurtz (Age 56)
    Chief Technical Officer
  • Mr. James Vollins J.D. (Age 54)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Dr. Ingrid C. Choong
    Sr. VP of Clinical Devel.
  • Dr. Colin Hislop M.D. (Age 65)
    MBBS, Sr. VP of Clinical & Devel. Operations













EIGR Stock - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price forecast for 2023?

2 analysts have issued 1 year price targets for Eiger BioPharmaceuticals' stock. Their EIGR share price forecasts range from $3.00 to $9.00. On average, they predict the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 1,481.1% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2023?

Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of 2023. Since then, EIGR stock has decreased by 69.6% and is now trading at $0.3584.
View the best growth stocks for 2023 here
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.47) EPS for the quarter. The biotechnology company earned $4.64 million during the quarter. Eiger BioPharmaceuticals had a negative net margin of 618.36% and a negative trailing twelve-month return on equity of 207.93%.

What ETF holds Eiger BioPharmaceuticals' stock ?

Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (8.47%), BlackRock Inc. (2.12%), RBF Capital LLC (0.88%), Geode Capital Management LLC (0.86%), DAVENPORT & Co LLC (0.47%) and Acadian Asset Management LLC (0.47%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $0.36.

How much money does Eiger BioPharmaceuticals make?

Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $15.88 million and generates $13.48 million in revenue each year. The biotechnology company earns $-96,780,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621.

This page (NASDAQ:EIGR) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -